Skip to Content

Vincristine Liposome Dosage

Medically reviewed on December 21, 2017.

Applies to the following strengths: 5 mg/31 mL

Usual Adult Dose for Acute Lymphoblastic Leukemia

2.25 mg/m2 intravenously over 1 hour every 7 days.

Renal Dose Adjustments

Data not available.

Liver Dose Adjustments

Data not available.

Dose Adjustments

The manufacturer suggests using caution when selecting a dose for elderly patients due to their greater frequency of decreased hepatic, renal, or cardiac function and concomitant disease or drug therapy.

The manufacturer recommends dose modifications for vincristine liposome related peripheral neuropathy. If the patient develops grade 3 or persistent grade 2 peripheral neuropathy, then interrupt therapy; discontinue if neuropathy remains at grade 3 or 4, and reduce dose to 2 mg/m2 if the neuropathy recovers to grade 1 or 2. If the patient has persistent grade 2 peripheral neuropathy following a dose reduction, then interrupt therapy for up to 7 days; discontinue if the neuropathy increases to grade 3 or 4, and reduce dose to 1.825 mg/m2 if neuropathy recovers to grade 1. If the patient has persistent grade 2 neuropathy after the second dose reduction, then interrupt therapy for up to 7 days; discontinue if the neuropathy increases to grade 3, and reduce the dose to 1.5 mg/m2 if the neuropathy recovers to grade 1.

Precautions

US BOXED WARNINGS:
-FOR IV USE ONLY - FATAL IF GIVEN BY OTHER ROUTES: Death has occurred with intrathecal use.
-VINCRISTINE SULFATE LIPOSOME has different dosage recommendations than vincristine sulfate. Verify drug name and dose prior to preparation and administration to avoid overdosage.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).

Consult WARNINGS section for additional precautions.

Dialysis

Data not available.

Other Comments

Vincristine liposome should be refrigerated between 36 degrees to 46 degrees Fahrenheit (2 degrees to 8 degrees Celsius) and should not be frozen.

The manufacturer's product information should be consulted for complete reconstitution and dilution recommendations.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide